The company made an upfront payment and will provide success-based milestones and royalties in exchange for global rights.

Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug ...

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Pipedrive, the easy and effective sales CRM for small businesses, today announced the winners of its 2024 Partner Awards, recognizing outstanding contributions from partners who have demonstrated ...

Kinaxis® , a global leader in end-to-end supply chain orchestration, has entered into a settlement agreement with Blue Yonder Group, Inc. to fully resolve all pending litigation matters between the ...

A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...

Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune ...